Benefit

HomeBenefit ▶ Ninth Annual ATS Foundation Research Program Benefit
Ninth Annual ATS Foundation Research Program Benefit

James Donohue and Sally Wenzel

David Center, MD (right), receiving the
2017 Breathing for Life Award from
Dean Schraufnagel, MD, ATS Foundation Chair

With an assortment of hors d’oeuvres, music, and dancing the ATS Foundation kicked off its Ninth Annual Research Program Benefit on Saturday, May 20, 2017. More than 650 attendees gathered at the Marriott Marquis Washington, DC to recognize David Center, MD, as the recipient of the 2017 Breathing for Life Award, as well as honor grant awardees, celebrate the ATS Foundation Research Program’s successes, and socialize with friends.

The Breathing for Life Award is given by the ATS Foundation to recognize philanthropy and scientific accomplishments. For the past 30 years, Dr, Center has served as chief of Pulmonary Medicine for Boston University. Jeffrey Glassroth, MD, one of the first fellows to train under Dr. Center, considers him a “triple threat.” “He’s a superb clinician, investigator, and teacher,” says Dr. Glassroth. “He’s also a person of tremendous integrity.”

The gala raised more than $425,000 from corporate, medical institution, and individual supporters with proceeds supporting research grants for young investigators.

In 2017, the ATS Foundation will fund more than 20 awards, including unrestricted research awards in pulmonary, critical care, and sleep medicine; research partner awards; and awards for outstanding alumni from the Methods in Epidemiologic, Clinical, and Operations Research (MECOR) program. Since 2004, the ATS Foundation Research Program has provided $16 million in grants to more than 210 investigators, who have gone on to secure $215 million in federal funding.

VIDEO: Dr. David Center, MD, 2017 Breathing for Life Awardee

VIEW: Photo gallery


The ATS Foundation thanks Genentech for support at the Sapphire Level; AstraZeneca LP at the Gold Level; FREEMAN, Gilead Sciences, Inc., Insmed Incorporated, Sunovion Pharmaceuticals, Inc., Teva Respiratory at the Silver Level; and Boehringer Ingelheim Pharmaceuticals, Inc., Boston Scientific Corporation, Inc., Circassia, Merck, and Vertex at the Bronze Level.

The ATS Foundation also thanks Boston University School of Medicine, Pulmonary, Allergy, Sleep and Critical Care Section & Boston University Pulmonary Research Center and the many individuals and medical institutions that have stepped forward to support the Research Program and young investigators in pulmonary, critical care, and sleep medicine.


The ATS supports the ATS Foundation’s administrative expenses, assuring that every dollar contributed goes directly to support programs. 

Donate